Navigation Links
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Date:10/8/2008

n women than in men(4).

The exact process by which PAH develops is not known. However, it appears to be associated with a variety of disease processes, including chronic thromboembolic disease (blood clots), connective tissue diseases, congenital heart disease and exposure to external factors including appetite suppressants or infectious diseases such as HIV(3).

1. Novartis has also conducted early stage research with imatinib mesylate

in another non-oncology disease called idiopathic pulmonary fibrosis

(IPF), a condition in which the lungs become scarred over time, making it

more and more difficult to breathe(6). Early clinical trial results in

IPF did not show a significant treatment benefit over placebo, and

clinical trials have therefore been halted.

About Gleevec

Gleevec(R) (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Follow-up is limited to 5 years. Gleevec is also indicated for the treatment of patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha (IFN-alpha) therapy; adult patients with relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL); adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements; adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-KIT mutation or with c-KIT mutational status unknown; adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase-negative or unknown; adult patients with unresectable, re
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
2. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
5. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
6. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
7. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
8. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
9. Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
10. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ("Bedrocan") ... of Directors, enhancing executive oversight and strengthening the ... licensed producer of medicinal cannabis in ... experience in producing and supplying government-regulated pharmaceutical-grade cannabis ... As previously announced in a press ...
(Date:8/21/2014)...  Cyberonics, Inc. (NASDAQ: CYBX ) today announced ... Quarterly highlights 1   Operating results for ... quarter of fiscal 2014, and other achievements, include: , ... 6.8%; , Strong international net sales of $13.2 million, ... , U.S. net product sales reached a new high of ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
(Date:8/21/2014)... report that children with autism appear to have excess ... with typical children. The scientists also believe it ... synapses through drug treatment. Synapses are the points ... communicate with each other. Having excess synapses may have ... neuroscientists at Columbia University Medical Center in New York ...
(Date:8/21/2014)... self-interest, humans do not protest being overcompensated, even ... State University,s Brains and Behavior Program have found. ... concerned than previously believed about the inequity of ... the journal Brain Connectivity . These findings ... their self-interest, indicating the interest humans show in ...
(Date:8/21/2014)... United Benefit Advisors (UBA), the ... pleased to announce Trinity Benefit Advisors as its ... Trinity Benefit Advisors is a full service firm ... clients. Their consultative approach is comprised of four ... and monitoring. Their dedication to effective results and ...
(Date:8/21/2014)... Centennial, CO (PRWEB) August 21, 2014 ... provider of in-home care, today announced that it has ... Care Pulse. This distinction illustrates Home Care Assistance’s commitment ... Assistance is to ensure that our client’s in the ... care available,” says Pete Lane, Owner of Home Care ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... Systems (Network-based, Independent, Hybrid), Maps and Navigation, ... and emergency services - Worldwide Market Forecasts ... segments the indoor location market into various ... of revenues. The report also identifies the ...
Breaking Medicine News(10 mins):Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:Influenced by self-interest, humans less concerned about inequity to others 2Health News:Influenced by self-interest, humans less concerned about inequity to others 3Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Home Care Assistance of Centennial Receives Home Care Pulse Certified – Trusted Provider Distinction 2Health News:Home Care Assistance of Centennial Receives Home Care Pulse Certified – Trusted Provider Distinction 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Indoor Location Market Worth $3.9 Billion by 2019 - New Report by MarketsandMarkets 4
... often been associated with serious side-effects. Researchers at the ... mice, found a way of utilising the positive effects ... is acted on, current research at the Academy shows. ... PNAS (Proceedings of the National Academy of Sciences). ...
... bacterial DNA that often carries antibiotic resistance is a master ... widely differing bacterial species, shows a study made by ... with Chalmers University of Technology. The results are published in ... More and more bacteria are becoming resistant to our ...
... , MONDAY, April 11 (HealthDay News) -- Young mothers ... have children, and they also consume more saturated fat, ... Examining data from Project EAT (Eating and Activity ... of Minnesota focused on the link between parental status, ...
... Normal daily fluctuations in blood pressure aren,t linked with the ... heart attack or stroke in the morning, a new study ... who underwent three types of sleep/wake cycle experiments designed to ... daily rise and fall in blood pressure. In all ...
... pain can significantly reduce disability in older adults, according to ... newsletter from The Gerontological Society of America ... Annual Scientific Meeting in November 2010, the current WHAT,S HOT ... managing pain and preserving function, and methods to improve the ...
... , SUNDAY, April 10 (HealthDay News) -- Obese patients taking ... lost an average of 22 pounds over a year, while ... study has found. Qnexa is a combination of ... the United States, currently available under a variety of brand ...
Cached Medicine News:Health News:Antibiotic resistance spreads rapidly between bacteria 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 3Health News:Effective pain management crucial to older adults' well-being 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 3Health News:Experimental Weight-Loss Drug Seems to Work: Study 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: